Myriad Genetics | MYGN - Gross Profit On Sales

Myriad Genetics reported $123.9M in Gross Profit on Sales for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Gross Profit On Sales Change
Accelerate Diagnostics AXDX:US USD 579K 501K
Agilent A:US USD 968M 44M
Becton, Dickinson and BDX:US USD 2.13B 56M
Bio Rad Laboratories BIO:US USD 397.33M 22.23M
Biocept BIOC:US USD -189000 2.78M
Bruker BRKR:US USD 365.9M 30.8M
Danaher DHR:US USD 4.94B 355M
Exact Sciences EXAS:US USD 405.84M 30.71M
Fluidigm FLDM:US USD 11.17M 1.95M
Hologic HOLX:US USD 617.9M 95M
Illumina ILMN:US USD 672M 45M
Johnson & Johnson JNJ:US USD 15.94B 56M
Mettler Toledo International MTD:US USD 632.14M 47.48M
Myriad Genetics MYGN:US USD 123.9M 17.9M
Nanostring Technologies NSTG:US USD 13.3M 2.52M
Orasure Technologies OSUR:US USD 49.59M 3.4M
Perkinelmer PKI:US USD 436.33M 29.29M
Quest Diagnostics DGX:US USD 777M 97M
Quidel QDEL:US USD 449M 41.5M
Repligen RGEN:US USD 96.06M 18.16M
Thermo Fisher Scientific TMO:US USD 4.74B 433M
Veracyte VCYT:US USD 53.47M 3.88M
Waters WAT:US USD 510.32M 108.87M